Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Cabaletta Bio Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update August 08, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum July 02, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201 June 14, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference May 29, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update May 15, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ May 13, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update March 21, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis March 20, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in Upcoming Investor Conferences in March February 27, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis February 01, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference January 31, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis January 08, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis November 06, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in November October 30, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Receives FDA Clearance of IND Application for Treatment of Systemic Sclerosis with CABA-201 October 02, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in Upcoming Investor Conferences in September September 19, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Participate in Multiple Upcoming Investor Conferences in September August 30, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio and WuXi Advanced Therapies Announce Expansion of GMP Manufacturing Agreement to Include CABA-201 August 22, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports Second Quarter 2023 Financial Results and Provides Business Update August 10, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Appoints Global Commercial Leader Shawn Tomasello to Board of Directors July 24, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Present at the Jefferies Healthcare Conference May 31, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Announces Closing of $100 Million Public Offering of Common Stock, Including Full Exercise of Option to Purchase Additional Shares May 22, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Announces Pricing of Public Offering of Common Stock May 17, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Announces Proposed Public Offering of Common Stock May 17, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Receives FDA Clearance of IND Application for CABA-201 for Treatment of Myositis May 16, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio Reports First Quarter 2023 Financial Results and Provides Business Update May 11, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Cabaletta Bio to Present at the American Society of Gene and Cell Therapy 26th Annual Meeting May 02, 2023 From Cabaletta Bio Via GlobeNewswire Tickers CABA Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.